Morgan Stanley’s Outlook Therapeutics OTLK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $27K | Buy |
16,956
+13,150
| +346% | +$8.16K | ﹤0.01% | 6716 |
|
|
2026
Q1 | $783 | Sell |
3,806
-2,218
| -37% | -$958 | ﹤0.01% | 7486 |
|
|
2025
Q4 | $9.52K | Buy |
6,024
+5,249
| +677% | +$8.39K | ﹤0.01% | 6907 |
|
|
2025
Q3 | $821 | Sell |
775
-424,824
| -100% | -$735K | ﹤0.01% | 7413 |
|
|
2025
Q2 | $681K | Buy |
425,599
+386,125
| +978% | +$616K | ﹤0.01% | 5311 |
|
|
2025
Q1 | $48.2K | Sell |
39,474
-17,918
| -31% | -$31.4K | ﹤0.01% | 6277 |
|
|
2024
Q4 | $108K | Buy |
57,392
+13,663
| +31% | +$56.2K | ﹤0.01% | 6023 |
|
|
2024
Q3 | $234K | Buy |
43,729
+30,843
| +239% | +$226K | ﹤0.01% | 5697 |
|
|
2024
Q2 | $95.1K | Buy |
12,886
+913
| +8% | +$7.33K | ﹤0.01% | 5981 |
|
|
2024
Q1 | $143K | Sell |
11,973
-13,251
| -53% | -$107K | ﹤0.01% | 5861 |
|
|
2023
Q4 | $199K | Buy |
25,224
+17,974
| +248% | +$152K | ﹤0.01% | 5706 |
|
|
2023
Q3 | $32K | Sell |
7,250
-2,810
| -28% | -$62.2K | ﹤0.01% | 6331 |
|
|
2023
Q2 | $350K | Buy |
10,060
+2,024
| +25% | +$55.2K | ﹤0.01% | 5394 |
|
|
2023
Q1 | $175K | Buy |
8,036
+3,278
| +69% | +$73.3K | ﹤0.01% | 5762 |
|
|
2022
Q4 | $103K | Buy |
4,758
+1,631
| +52% | +$35.5K | ﹤0.01% | 5963 |
|
|
2022
Q3 | $75K | Buy |
3,127
+609
| +24% | +$14.2K | ﹤0.01% | 6222 |
|
|
2022
Q2 | $52K | Sell |
2,518
-108
| -4% | -$3.1K | ﹤0.01% | 6591 |
|
|
2022
Q1 | $94K | Buy |
2,626
+616
| +31% | +$19.2K | ﹤0.01% | 6352 |
|
|
2021
Q4 | $55K | Sell |
2,010
-9,736
| -83% | -$347K | ﹤0.01% | 6766 |
|
|
2021
Q3 | $509K | Buy |
11,746
+5,514
| +88% | +$266K | ﹤0.01% | 5487 |
|
|
2021
Q2 | $311K | Buy |
6,232
+5,052
| +428% | +$234K | ﹤0.01% | 5787 |
|
|
2021
Q1 | $53K | Sell |
1,180
-70
| -6% | -$2.68K | ﹤0.01% | 6330 |
|
|
2020
Q4 | $33K | Buy |
+1,250
| New | +$26.1K | ﹤0.01% | 6291 |
|
|
2020
Q2 | – | Sell |
-42
| Closed | -$1K | – | 6688 |
|
|
2020
Q1 | $1K | Buy |
+42
| New | +$697 | ﹤0.01% | 6476 |
|
|
2019
Q4 | – | Sell |
-2
| Closed | – | – | 6727 |
|
|
2019
Q3 | $0 | Sell |
2
-191
| -99% | -$7.37K | ﹤0.01% | 6715 |
|
|
2019
Q2 | $8K | Buy |
193
+132
| +216% | +$6.15K | ﹤0.01% | 6194 |
|
|
2019
Q1 | $9K | Hold |
61
| – | – | ﹤0.01% | 6210 |
|
|
2018
Q4 | $5K | Sell |
61
-39
| -39% | -$4.8K | ﹤0.01% | 6295 |
|
|
2018
Q3 | $16K | Hold |
100
| – | – | ﹤0.01% | 6201 |
|
|
2018
Q2 | $14K | Hold |
100
| – | – | ﹤0.01% | 6230 |
|
|
2018
Q1 | $14K | Hold |
100
| – | – | ﹤0.01% | 6199 |
|
|
2017
Q4 | $21K | Buy |
100
+2
| +2% | +$415 | ﹤0.01% | 6061 |
|
|
2017
Q3 | $22K | Sell |
98
-35
| -26% | -$6.37K | ﹤0.01% | 5996 |
|
|
2017
Q2 | $21K | Hold |
133
| – | – | ﹤0.01% | 6070 |
|
|
2017
Q1 | $57K | Buy |
133
+40
| +43% | +$19.9K | ﹤0.01% | 5792 |
|
|
2016
Q4 | $45K | Sell |
93
-19
| -17% | -$10.6K | ﹤0.01% | 5778 |
|
|
2016
Q3 | $76K | Buy |
112
+49
| +78% | +$31.1K | ﹤0.01% | 5417 |
|
|
2016
Q2 | $34K | Buy |
+63
| New | +$37.6K | ﹤0.01% | 5665 |
|
Other funds holding OTLK
PA
HF
GWM
Morgan Stanley's OTLK Position: Q2 2026 in Review
Morgan Stanley increased its Outlook Therapeutics (OTLK) stake by 346% in Q2 2026, buying an estimated $8.16K and bringing the position to 16,956 shares worth $27K. The position accounts for ﹤0.01% of the portfolio, ranked #6716.
Morgan Stanley first reported a position in OTLK in Q2 2016 and has held it in 38 quarters since. The position peaked at $681K in Q2 2025. 70 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.
- Morgan Stanley held 16,956 shares of Outlook Therapeutics worth $27K as of Q2 2026.
- Morgan Stanley bought 13,150 Outlook Therapeutics shares in Q2 2026, an estimated $8.16K.
- Outlook Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6716 holding.
- Morgan Stanley first reported a position in Outlook Therapeutics in Q2 2016 and has held it in 38 quarters since.
- Morgan Stanley's Outlook Therapeutics position peaked at $681K in Q2 2025.
- 70 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.